Northwest Biotherapeutics, Inc.
NWBO
$0.2984
$0.01525.37%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -28.22M | -19.37M | -17.87M | -18.31M | -13.98M |
| Total Depreciation and Amortization | 501.00K | 522.00K | 516.00K | 505.00K | 421.00K |
| Total Amortization of Deferred Charges | 858.00K | 551.00K | 491.00K | 576.00K | 366.00K |
| Total Other Non-Cash Items | 4.60M | 6.27M | -168.00K | 1.55M | 1.25M |
| Change in Net Operating Assets | 2.09M | 3.80M | 833.00K | 3.28M | -5.02M |
| Cash from Operations | -20.18M | -8.23M | -16.20M | -12.41M | -16.96M |
| Capital Expenditure | -78.00K | -176.00K | -521.00K | -239.00K | -418.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -78.00K | -176.00K | -521.00K | -239.00K | -418.00K |
| Total Debt Issued | 12.30M | 4.82M | 10.00M | 7.10M | 10.65M |
| Total Debt Repaid | -382.00K | -802.00K | -249.00K | -- | -175.00K |
| Issuance of Common Stock | 4.22M | 7.14M | 3.08M | 1.31M | 119.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.00 | 267.00K | 4.31M | 3.62M | 3.43M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -200.00K | 200.00K | 0.00 | 50.00K | 393.00K |
| Cash from Financing | 15.94M | 11.62M | 17.14M | 12.09M | 14.42M |
| Foreign Exchange rate Adjustments | 3.55M | -3.15M | -17.00K | 912.00K | -1.01M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -764.00K | 58.00K | 403.00K | 352.00K | -3.97M |